StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho is Positive on Celgene (CELG)
October 27, 2017 10:31 AM
Mizuho Securities maintains Buy on Celgene (NASDAQ: CELG) price target of $158.00.Analyst Salim Syed says the Ozanimod Phase 3 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
Celgene (CELG) Says Results from First Phase III Trial of Oral Ozanimod Versus an Active Comparator in Relapsing MS Presented at MSParis2017
October 27, 2017 9:06 AM
Celgene (CELG) PT Lowered to $125 at Jefferies; Reiterates Buy
October 27, 2017 8:40 AM
Cantor Fitzgerald Downgrades Celgene (CELG) to Neutral
October 27, 2017 7:36 AM
UPDATE: Morgan Stanley Upgrades Celgene (CELG) to Equalweight
October 27, 2017 5:57 AM
JMP Securities Downgrades Celgene (CELG) to Market Perform Citing Valuation
October 27, 2017 3:16 AM
Raymond James Double Downgrades Celgene (CELG) to Market Perform
October 26, 2017 3:57 PM
Wells Fargo Downgrades Celgene (CELG) to Market Perform, Cuts PT 'on Serial Disappointment'
October 26, 2017 10:52 AM
Celgene (CELG) Maintained Outperform at Oppenheimer, Defends Name
October 26, 2017 10:40 AM
Celgene (CELG) Tops Q3 EPS by 4c, Sales Miss; Raises Low End of FY EPS Guidance, Offers 2020 Targets
October 26, 2017 7:34 AM
